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Purpose: This work aims to characterise a proton pencil-beam scanning (PBS) and passive double 20 
scattering (DS) systems as well as to measure parameters relevant to the relative biological 21 
effectiveness (RBE) of the beam using a silicon-on-insulator (SOI) microdosimeter with well-defined 22 
3D sensitive volumes (SV). The dose equivalent downstream and laterally outside of a clinical PBS 23 
treatment field was assessed and compared to that of a DS beam. 24 
Methods: A novel silicon microdosimeter with well-defined 3D SVs was used in this study. It was 25 
connected to low noise electronics, allowing for detection of lineal energies as low as 0.15 keV/μm. 26 
The microdosimeter was placed at various depths in a water phantom along the central axis of the 27 
proton beam, and at the distal part of the spread out Bragg peak (SOBP) in 0.5 mm increments. The 28 
RBE values of the pristine Bragg peak (BP) and SOBP were derived using the measured 29 
microdosimetric lineal energy spectra as inputs to the modified microdosimetric kinetic model 30 
(MKM). Geant4 simulations were performed in order to verify the calculated depth-dose distribution 31 
from the treatment planning system (TPS) and to compare the simulated dose-mean lineal energy to 32 
the experimental results. 33 
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Results: For a 131 MeV PBS spot (124.6 mm R90 range in water), the measured dose-mean lineal 34 
energy 𝑦𝐷���� increased from 2 keV/µm at the entrance to 8 keV/µm in the BP, with a maximum value of 35 
10 keV/µm at the distal edge. The derived RBE distribution for the PBS beam slowly increased from 36 
0.97 ± 0.14 at the entrance to 1.04 ± 0.09 proximal to the BP, then to 1.1 ± 0.08 in the BP, and steeply 37 
rose to 1.57 ± 0.19 at the distal part of the BP. The RBE distribution for the DS SOBP beam was 38 
approximately 0.96 ± 0.16 to 1.01 ± 0.16 at shallow depths, and 1.01 ± 0.16 to 1.28 ± 0.17 within the 39 
SOBP. The RBE significantly increased from 1.29 ± 0.17 to 1.43 ± 0.18 at the distal edge of the 40 
SOBP.     41 
Conclusions: The SOI microdosimeter with its well-defined 3D SV has applicability in characterising 42 
proton radiation fields and can measure relevant physical parameters to model the RBE with sub-43 
millimetre spatial resolution. It has been shown that for a physical dose of 1.82 Gy at the BP, the 44 
derived RBE based on the MKM model increased from 1.14 to 1.6 in the BP and its distal part. Good 45 
agreement was observed between the experimental and simulation results, confirming the potential 46 
application of SOI microdosimeter with 3D SV for quality assurance in proton therapy. 47 
Key words: microdosimetry, proton therapy, Pencil Beam Scanning (PBS), Silicon on Insulator (SOI), 48 
RBE, 3D sensitive volume 49 
I. INTRODUCTION 50 
Radiotherapy with proton and ion beams is advantageous compared to X-ray radiotherapy due to 51 
the highly localised energy deposition, allowing for conformal dose distributions. Both proton and ion 52 
beams have a finite range in matter which allows for increased sparing of healthy tissue. Unlike ion 53 
beams, protons do not produce projectile fragments beyond the Bragg peak (BP). Nevertheless, 54 
inelastic reactions with tissue create a small number of secondary protons, neutrons, gamma rays and 55 
heavier recoil nuclei. The distribution of these secondary products changes with depth. The secondary 56 
proton production mainly contributes to the halo around the primary proton beam while the secondary 57 
neutrons cause a high RBE downstream of the spread-out Bragg peak (SOBP) irradiating normal 58 
tissue [1].   59 
The standard proton radiotherapy practice is to use RBE weighted absorbed doses calculated 60 
using a generic RBE of 1.1 [2]. Data presented in Paganetti [2], based on the analysis of many 61 
publications, has demonstrated that the proton RBE increases with depth in the SOBP from ~1.1 to 62 
1.7 at 2 Gy per fraction when the published cell-lines are averaged. The recently published work by 63 
Marshall et. al. [3] measured cell survival data using clonogenic human fibroblasts (AG01522) for a 64 
proton pencil beam scanning (PBS) with maximum energy of 219.65 MeV and demonstrated that the 65 
generally accepted RBE of 1.1 through the SOBP  underestimates the effect of increased LET for 66 
distal regions of clinical proton beams for acute exposures. Additionally, the experiments have shown 67 
that towards the distal part of the SOBP, the biologically effective dose (biological dose) increased 68 
during fractionated proton exposure compared to single high dose fraction (acute exposure), 69 
especially with reduced dose per fraction.   70 
The passive double scattering (DS) beam and PBS treatment delivery may have different RBE 71 
values due to different proton spectra at a point of interest, especially those points closer to the end of 72 
the SOBP. Appreciation of the importance of a variable RBE in proton therapy has led to 73 
radiobiological treatment optimization based on the dose averaged LET (LETd) [4, 5]. More recently, 74 
analytical models of LETd predictions have been used for fast inverse treatment planning optimization 75 
in intensity modulated proton therapy (IMPT) [6] which changes the therapeutic ratio quantification. 76 
Analysis of a number of published experimental radiobiological in vitro and in vivo studies in proton 77 
therapy was formalised recently in a relationship of the proton beam’s RBE against LETd, linear 78 
quadratic model (LQM) parameters (α/β)x, and dose using a robust non-linear regression technique 79 
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[7]. Therefore, there is much interest in studying the RBE in proton therapy for better planning 80 
biological dose and improved quantification of treatment outcomes.   81 
The RBE prediction in heavier ions is modelled by empirical models such as the microdosimetric 82 
kinetic model (MKM) and the local effect model (LEM) [8, 9].  83 
Detailed considerations of the MKM’s theory can be found in Hawkins [8]. The RBE calculation 84 
method used in this study is based on the modified MKM as introduced by Kase et al. [10]. This is a 85 
combined model of microdosimetry and repair of radiation-induced lesions [11]. In this work, the 86 
advantage of using MKM for RBE calculations is the ability to use experimentally measured 87 
microdosimetric distribution of lineal energies (y). This microdosimetric quantity is used to describe 88 
the energy deposition event by event in a micron size sensitive volume (SV) along a particle’s track, 89 
given by: 90 
𝑦 =
𝐸
< 𝑙 >
 (1) 
where E is the energy deposited for a single event in a SV with an average chord length <l>. The 91 
spectrum of stochastic events 𝑓(𝑦) for all primary and secondary particles generated during an 92 
exposure of tissue to ionizing radiation can be derived from the spectrum of energy deposition events. 93 
The dose lineal energy distribution d(y) is given by: 94 
𝑑(𝑦) =
𝑦𝑓(𝑦)
𝑦𝐹���
 (2) 
where 𝑦𝐹��� = ∫ 𝑦𝑓(𝑦)𝑑𝑦
∞
0   is the frequency-mean lineal energy. Another important microdosimetric 95 
parameter is the dose-mean lineal energy  𝑦𝐷���� = ∫ 𝑦𝑑(𝑦)𝑑𝑦
∞
0 ; details of microdosimetry theory can be 96 
found elsewhere [12, 13]. The 𝑦𝐷���� is used to determine the α parameter in the Linear Quadratic Model 97 
(LQM) in equation (3) which describes cell survival in radiation field of interest and used later for 98 
RBE derivation: 99 
 𝑆 =  𝑒𝑒𝑒 [ − 𝛼𝛼 −  𝛽𝛼2] (3) 
where 𝛼 =  𝛼𝑜 +
𝛽
𝜌𝜌𝑟𝑑
2  𝑦∗, 𝛽 is a parameter of the LQM survival curve (which assumes LET 100 
independence), ρ is density of cell medium and can be assumed water (ρ = 1g/cm3),  𝑟𝑑 is the radius of 101 
sub-cellular domain in the MKM and  y∗, the saturation-corrected dose-mean lineal energy, which 102 
takes into account the overkilling effect for excessive local energy deposition [12], determined from 103 
experimentally measured microdosimetric spectra using formula (4).  104 
 105 
where yo = 150 keV/µm in order to match the calculation method used at HIMAC [11]. It is clearly 106 
seen that for y<<y0, y∗ converges to 𝑦𝐷����. 107 
The linear relation of α versus LET and β independence on LET were also confirmed recently from 108 
parametrization of cell survival studies versus dose dependence using LQM for therapeutic proton 109 
pencil beam [3]. They agreed in agreement with a phenomenological RBE model based on LQM [14] 110 
that well justified application of MKM for RBE derivation for proton radiation fields. Validation of 111 
the MKM and its parameters was demonstrated in many types of cell survival studies. For instance, 112 
the human salivary gland (HSG) tumour cells with MKM parameters, αo = 0.13 Gy-1, β = 0.05Gy-2, rd 113 
= 0.42 µm [11]. The mentioned parameters of the HSG cell line were used as an example of RBE 114 
derivation in this study. The RBE is proton dose dependent and related to particular survival fractions 115 
S(Dp) and can be obtained from (3) using the following formula: 116 
 
𝑅𝑅𝐸 = 𝐷𝑋
𝐷𝑝
=
�𝛼𝑋2+4𝛽𝑋�𝛼𝑝𝐷𝑝+𝛽𝑝𝐷𝑝2�−𝛼𝑋
2𝛽𝑋𝐷𝑝
, 
(5) 
 
𝑦∗ =
𝑦𝑜2 ∫ �1 − 𝑒𝑒𝑒(−𝑦2/𝑦𝑜2)�𝑓(𝑦)𝑑𝑦
∞
0
∫ 𝑦𝑓(𝑦)∞0 𝑑𝑦
 
(4) 
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where αp is a linear function of y∗, Dp and DX are protons and reference X-ray radiation doses 117 
necessary for the same cell survival S, respectively. 200 kVp X-rays are used as a reference radiation 118 
for HSG cells for which αX = 0.164 Gy-1 and βp=βX = 0.05 Gy-2 [10].    119 
While many quality assurance (QA) tools have been developed and implemented in the clinical 120 
setting regarding absorbed dose, range and fluence of protons [15], there is still a lack of practical 121 
experimental QA tools to characterise the physical microdosimetric parameters of the proton beam. 122 
These parameters can be used as the input parameters for the MK model to calculate the RBE for 123 
therapeutic proton beams. The tissue equivalent proportional counter (TEPC or Rossi counter) is the 124 
currently accepted gold standard for microdosimetry, and has been used to measure the 125 
microdosimetric spectra of therapeutic proton beams of different energies and determine RBE at 126 
different depths, presented in [16]. Furthermore, using TEPC measurements, RBE values have been 127 
calculated using the MKM in a 155 MeV proton beam at the heavy ion medical accelerator in Chiba 128 
(HIMAC) [10]. Additionally, the group at INFN Legnaro laboratories has proposed the mini TEPC to 129 
avoid pile up and to assess the RBE of the radiation by linking the physical microdosimetric 130 
parameters with the corresponding biological response. The feasibility of the mini TEPC has 131 
previously been tested in a 62 MeV proton beam [17] and recently used for monenergistic 12C ion 132 
beam at CNAO [18]. Studies using the TEPC for microdosimetric measurements for both in-field and 133 
out-of-field  in low dose rate 12C and 7Li ion pencil beams have also been reported [19, 11]. While the 134 
TEPC is the gold standard for microdosimetry its large size means that spatial resolution is limited, 135 
with the addition of pile up effect in therapeutic proton beams. Additionally, the TEPC’s high voltage 136 
bias and gas supply requirements make it less ideal for routine QA in clinical environments. For this 137 
reason, experimental microdosimetric parameters have never been obtained at the Bragg peak and its 138 
distal part with high spatial resolution. Alternatively, solid state microdosimetry including ΔE-E 139 
monolithic silicon detectors [20, 21] and silicon on insulator (SOI) microdosimetry [22] were 140 
introduced at Politechnico di Milano, Italy and at the Centre for Medical Radiation Physics (CMRP), 141 
University of Wollongong, Australia, respectively. These have been used for characterization of 142 
neutron and proton therapeutic beams.  143 
SOI microdosimetry is based on an array of micron sized SV mimicking the dimensions of cells. 144 
These microdosimeters are used for determining the energy deposited event by event produced by 145 
primary and secondary charged particles. The SOI microdosimeter has advantages of having a small 146 
SV size (of the order of 10 µm thickness), low operational bias (5-10 V) and a high spatial resolution 147 
of the order of 100 µm which is limited by the accuracy of placing the microdosimeter in a phantom.  148 
Progress in development of SOI microdosimeters at the CMRP and their applications in proton, 149 
heavy ion and neutrons fields were well outlined in [23] and references within.  150 
Recently, the CMRP has developed and fabricated SOI microdosimeters consisting of micron 151 
sized well-defined 3D SVs known as “bridge” microdosimeters. The device was previously 152 
characterised in detail and successfully applied in 12C ion therapy at HIMAC, Japan [24, 25]. Using 153 
this microdosimeter we were able to measure the microdosimetric quantity 𝑦𝐷���� , which was used as an  154 
input parameter for the MKM to calculate the  RBE10 corresponding to 10% of human salivary gland 155 
(HSG) cell survival. The corresponding biological doses (𝑅𝑅𝐸10 𝑒 𝛼) in-field and out-of-field were 156 
obtained with submillimeter spatial resolution and compared to TEPC measurements. The RBE10 157 
distributions obtained with the silicon microdosimeter after converting the response to tissue matches 158 
very well with TEPC measurements. Due to the high spatial resolution of the bridge microdosimeter, 159 
more detailed measurements of 𝑦𝐷���� and its corresponding RBE10 were obtained at the distal end of the 160 
SOBP compared to the TEPC. 161 
The primary aim of this paper is to introduce an innovative microdosimetry probe, the MicroPlus 162 
(µ+) probe, based on the SOI bridge microdosimeter as a new QA tool for the characterization of 163 
mixed radiation fields in proton therapy. The bridge microdosimeter has been utilised for the first time 164 
for microdosimetric parameters measurements in a PBS and DS proton beam at the Massachusetts 165 
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General Hospital (MGH) Francis H. Burr Proton Beam Therapy Center followed by MKM based 166 
RBE calculation. Measurements of the dose averaged lineal energy profile with submillimetre spatial 167 
resolution close to and at the distal part of the pristine BP and SOBP and derived RBE was the focus 168 
of this work.    169 
Additionally, dose equivalent calculated from the measured microdosimetric spectra laterally 170 
out-of-field and downstream of the SOBP delivered with PBS is presented.  Geant4 Monte Carlo 171 
simulation of the response of the bridge microdosimeter is compared to the experimental results. 172 
MATERIAL AND METHOD 173 
A. 3D bridge microdosimeter and microdosimetric probe 174 
The SOI microdosimeter in this study is an array of 3D SVs with size 30 × 30 × 10 µm3, 175 
fabricated on a high resistivity 10 μm thick n-SOI active layer, bonded to a 400 µm thick low 176 
resistivity supporting wafer. The well-defined 3D SVs has uniform charge collection [25].  SOI 177 
microdosimeters, in contrast to the TEPCs, provide high spatial resolution necessary where particle 178 
LET varies significantly over a short distance e.g. towards the end of the BP.  179 
 
a) 
 
b) 
Figure 1 a) The CMRP microdosimeter chip in DIL package (left) and SEM image of the bridge 180 
microdosimeter sensitive volumes array (right). b) 𝜇+ microdosimetric probe in waterproof Polymethyl 181 
Methacrylate (PMMA) sheath. 182 
Figure 1 shows the microdosimeter mounted on a dual in-line (DIL) package and a scanning electron 183 
microscope (SEM) image of section of the microdosimeter’s 3D SVs. A well-defined 3D SV of 184 
rectangular parallelepiped (RPP) shape helps correctly define the mean chord length for accurate 185 
lineal energy determination. Figure 1b shows the microdosimetric probe, named MicroPlus probe 186 
(𝜇+), developed at the CMRP, based on an SOI  microdosimeter with an array of 3D SVs connected 187 
to a low noise spectroscopy-based readout circuit. Taking into account the noise threshold in 188 
electronics the probe allows measurements of deposited lineal energy above or equal 0.15 keV/µm in 189 
tissue. The readout electronics of the 𝜇+ probe is located 10 cm away from the detector to keep the 190 
readout circuitry out of the primary radiation field and avoid radiation damage to the electronics. The 191 
µ+ probe is covered by a PMMA sheath to allow the microdosimeter to be operated in water. The 192 
microdosimetric probe was mounted in a water phantom using an X-Y drive to remotely control the 193 
detector location in the phantom using computer driven stepper motors. 194 
B. Delivery system of Passive Scattering and Pencil Beam Scanning.  195 
At the MGH proton facility, the cyclotron produces a proton beam with an energy of 235 MeV which 196 
is then degraded and transported to a gantry treatment room with either a PBS or DS delivery system. 197 
The passively scattered proton fields use an IBA universal nozzle and a range modulator is used to 198 
form a SOBP. A 5 × 5 cm2 brass aperture is placed close to the patient to reduce the proton penumbra 199 
[26]. 200 
The PBS delivery system produces a pencil beam with a FWHM between 20 and 35 mm with a 201 
range of 32 to 7 cm in water, respectively [27]. In this experiment, a pencil-beam with a σ of 11 mm 202 
(FWHM = 2.3548 × σ = 25.9 mm) in air at isocenter, and a range at the distal 90% of the depth dose 203 
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R90 = 124.6 mm, was used for measuring the lineal energy distribution and MKM-based derived RBE 204 
of an individual PBS spot.   205 
 206 
Figure 2 Treatment plan for the 5 × 5 × 5 cm3 dose cube irradiation using PBS. 207 
This individual spot, as well as a 5 × 5 × 5 cm3 dose cube using PBS and DS, were delivered in a 208 
water phantom. Figure 2 shows the coronal and sagittal views of the delivered dose for the 5 × 5 × 5 209 
cm3 dose cube treatment plan using PBS. Dose delivered to the target volume was 1.82 Gy in the 210 
middle of the SOBP. 211 
C. Silicon to tissue equivalent conversion 212 
The lineal energy deposition was measured in silicon and to obtain the simulated energy in a 213 
tissue equivalent material a conversion was therefore necessary. A silicon-tissue conversion factor of 214 
0.58 was obtained by calculating the energy deposition in the silicon SV exposed to the 150 MeV 215 
PBS spot proton radiation field along the Bragg curve, by means of Geant4. The energy deposition 216 
distribution in a tissue equivalent material (striated muscle) SV was calculated for the same radiation 217 
field conditions, the size of the tissue SV was varied to obtain the same energy deposition spectrum as 218 
the silicon SV The tissue equivalence conversion factor κ is then defined as the ratio of the length lSi 219 
of the silicon SV to the length ltissue of the tissue SV. The conversion factor was found not to vary over 220 
the range of proton energies investigated and so a single value of 0.58 was adopted for all beam 221 
irradiation methods.  More detail about this method can be found in [28].   222 
D. Determination of dose equivalent out-of-field  223 
The dose equivalent (H) was evaluated outside of the target volume laterally and downstream of the 224 
SOBP to quantify the effects of ionizing radiation on surrounding healthy tissue and is defined as: 225 
𝐻 = 𝛼𝑇𝑇  𝑄�  = 𝛼𝑇𝑇 �𝑄(𝑦)𝑑(𝑦)𝑑𝑦 
(6) 
where H is the dose equivalent, Q(y) is a Quality Factor obtained from ICRU 40 [29], and 𝛼𝑇𝑇 is the 226 
absorbed dose in tissue. Q(y) is given by: 227 
𝑄(𝑦) =
𝑎1
𝑦 �
1− 𝑒�−𝑎2𝑦2−𝑎3𝑦3�� , (7) 
With coefficients:    a1 = 5510 keV/µm 228 
 a2 = 5.10-5 µm2/keV2 229 
 a3 = 2.10-7 µm3/keV3 230 
The absorbed dose in silicon is calculated by integrating the multichannel analyser (MCA) energy 231 
deposition spectra and dividing by the mass of the silicon 3D SVs. The DTE can then be obtained by 232 
multiplying the dose to silicon by the average tissue equivalent conversion factor of 0.58. This method 233 
was used previously in our work [30, 31]. 234 
E. Geant4 simulation 235 
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E1. Proton pencil beam scanning simulation 236 
The PBS delivery was modelled using Geant4 version 10.0, and compared to dose data obtained 237 
with a Zebra (IBA Dosimetry, Germany) multilayer ionisation chamber detector [32] at MGH.  238 
 239 
Figure 3 Geometrical schematic showing two SVs of the bridge microdosimeter, connected by a silicon 240 
bridge.  241 
The initial proton energy distribution is considered Gaussian with a 1% sigma (𝜎). The proton spot 242 
size was simulated with 𝜎 = 11 mm. A slab of 30 × 30 × 30 cm3 water was placed in air, 40 cm away 243 
from the beam nozzle. 244 
The response of the bridge microdosimeter to a PBS spot depth-dose irradiation in a water 245 
phantom was simulated. The microdosimeter was modelled as an array of 58 × 72 SVs which were 246 
interconnected by Si bridges with dimensions of 20 × 15 × 10 µm3. Each SV was modelled as a RPP 247 
with dimensions of 30 × 30 × 10 µm3 and is shown in Figure 3. 248 
E2. Average path length simulation of the bridge microdosimeter in proton PBS 249 
Geant4 simulations were performed to calculate the average geometric path length of particles 250 
traversing through the SV of the bridge microdosimeter in the proton field. The simulated SV is 251 
modelled as a vacuum to remove any physical interactions within the SV from traversing particles, 252 
whilst maintaining the angular dependence of the radiation field incident on the microdosimetric SV. 253 
The average path length of the microdosimeter SV was calculated for all primary and secondary ions 254 
and at different depths in water phantom. More details describing the process can be found in [28].  255 
III. RESULTS  256 
A. Spot PBS field characterization 257 
Figure 4 gives the microdosimetric spectra obtained with the µ+ probe in response to the 131 MeV 258 
PBS spot  (R90 = 124.6 mm) measured at different depths in water: 22, 50, 90, 100, 110, 122, 125, 259 
126, 129, 137 and 150 mm. While the microdosimeter active area is small all measurements were 260 
done using a reduced beam current in the spot delivery (<0.1 nA) in order to avoid possible pile up 261 
effects in the read-out electronics. The range of lineal energies produced by the proton spot in water 262 
ranged from 0.3 to 5 keV/µm at the entrance, 0.5 to 6 keV/µm in the proximal part of the BP, and  0.6 263 
to 45 keV/µm in the distal part of the BP.  264 
Downstream of the BP, at depth 137 mm and further, a few events with lineal energies up to 200 265 
keV/µm were identified in addition to events associated with neutron induced recoil protons. These 266 
events are due to carbon, oxygen and silicon recoils, as well as alpha particles from Si(n,α) reactions 267 
occuring in the silicon and surrounding materials. These few high lineal energy events can 268 
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significantly change the 𝑦𝐷���� values downstream of the BP and can lead to substantial 𝑦𝐷���� uncertainties, 269 
which has been noted in [10] using TEPC. 270 
Figure 5 shows the dose mean lineal energy, 𝑦𝐷���� measured using the bridge microdosimeter 271 
irradiated by the 131 MeV PBS spot beam as a function of depth in water. 𝑦𝐷���� values were calculated 272 
from the microdosimetric spectra measured at the particular depth in water as presented in Fig. 4. The 273 
approximate 𝑦𝐷���� values were about 2 keV/µm in the plateau region, around 3 to 5 keV/µm in the 274 
proximal part of the BP, and around 9 to 10 keV/µm at the end of the BP. 275 
  
a) b) 
Figure 4 Microdosimetric spectra obtained using the bridge microdosimeter in the water phantom at a) depths 276 
of 22 mm to 122 mm and b) 125 mm to 150 mm for a 131MeV proton PBS spot. 277 
 278 
Figure 5 Dose-mean lineal energy 𝑦𝐷���� obtained using the bridge microdosimeter as a function of depth in 279 
water for a proton PBS spot. 280 
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a) 
 
b) 
 
Figure 6 a) Depth-dose distribution for the 131 MeV proton pencil beam based on Zebra measurements (black 
line) and derived RBE distribution (blue line) determined by (5) based on the microdosimetric spectra 
measured with the bridge microdosimeter. b) detailed depth-dose distribution from 100-135mm depth.  
The RBE based on HSG cell survival (modeled using eq. 5) at different depths in water based on 281 
measured percentage depth dose (PDD) with maximum absorbed dose of 1.82 Gy at the BP are shown 282 
in figure 6. The RBE values were 0.96 ± 0.14 in the plateau region (up to 100 mm depth). This RBE 283 
value was slightly less than 1 because the dose-mean lineal energy used for α simulation according to 284 
the MKM (eq. 3)  for protons at those depths is less than 4.3 keV/µm [10] corresponding to the X-ray 285 
radiation reference used for the RBE derivation (eq. 5). The derived RBE values were 1.04 ±  0.08 at 286 
122 mm depth, corresponding to  approximately 90% of prescribed dose in the peak, 1.10 ± 0.08 at 287 
123 mm depth, and 1.57 ± 0.19 at 129 mm depth, coresponding to the distal falloff of the BP where 288 
the dose was approximately 13% of the prescribed dose at the BP. The RBE along the Bragg peak 289 
changes due to variations in the microdosimetric spectra and dose. A comparison of RBE values at 290 
two points with equal absorbed doses can show how the RBE depends solely on the changing 291 
microdosimetric spectra, represented by variation in the 𝑦𝐷.  The RBE values calculated at points on 292 
the leading and falling edges of the BP (depths of 123 and 126 mm) are 1.10 and 1.40, respectively. 293 
With the absorbed dose corresponding to 80% of the BP dose at both points, this relatively large 294 
increase in RBE demonstrates how the increasing 𝑦𝐷 values of the microdosimetric spectra 295 
contributes strongly to changes in RBE along the depth of the proton field.    296 
B. Out-of-field dose equivalent in PBS  and comparison to passive scattering 297 
Figure 7 shows the microdosimetric spectra measured in the water phantom using the µ+ probe at 298 
the distal part and downstream of the PBS delivered SOBP (5× 5 × 5 cm3 dose cube) with ranges R80 299 
of 129.8 mm and R90 of 125.7 mm in water. The dose delivered was 1.82 Gy in the center of SOBP 300 
and the measurements were performed downstream of the SOBP at depth 140 and 150 mm in the 301 
water phantom. The measured dose equivalent out of field was normalised per 1 Gy dose delivered to 302 
the middle of the SOBP. The accuracy of the microdosimeter placement for depths in the water 303 
phantom was ± 1 mm which contributes to the uncertainty in these measurements. The 304 
microdosimetric spectra at depths of 140 and 150 mm were mostly dominated by recoil protons 305 
generated from neutron interactions in water and a few high LET alpha particles produced as the 306 
result of inelastic Si(n, α) reactions and C and Si recoils. The microdosimetric spectrum at 150 mm 307 
depth is noisy due to low statistics. The dose equivalent measured at a depth of 140 mm 308 
(corresponding to approximately 12% of prescribed dose in the middle of the SOBP) and at 150 mm 309 
in water were 20.4 ± 0.36 mSv/Gy and 0.56± 0.06 mSv/Gy, respectively. The average quality factor 310 
calculated using equation (6) at a depth of 140mm and 150mm were 3.04 and 2.49, respectively. 311 
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 312 
Figure 7 Microdosimetric spectra obtained with the µ+ probe at depths of 140 mm and 150 mm in the water 313 
phantom for a PBS SOBP field with target volume 5 × 5 × 5 cm3. 314 
Table 1 shows the estimated dose equivalent per 1Gy, delivered in a middle of SOBP, along the 315 
central axis downstream of the PBS SOBP beam at depths of 140 and 150 mm in water and 100 mm 316 
laterally from the edge of the field at a depth of 62.5 mm (isocenter). These values are compared with 317 
previously published data measured at the same facility using a passively scattered beam to deliver 318 
prostate and spinal medulloblastoma treatments fields [31]. It can be seen that the dose equivalent in 319 
the PBS SOBP delivery was smaller than the passively double scattering delivery. It has been 320 
demonstrated that the dose equivalent downstream of the SOBP were almost the same for different 321 
energies of protons used for prostate treatment (proton range of 288 mm in water and modulated to 322 
104 mm) and spinal medulloblastoma (proton range of 96 mm in water and modulated to 74 mm). 323 
The dose equivalent for lateral out of field position is much smaller in PBS SOBP in comparison with 324 
passively double scattering delivery that confirms the advantage of PBS delivery in reducing scattered 325 
protons to patient’s normal tissue.  326 
TABLE I.  𝑦𝐷��� and dose equivalent data measured with µ+ probe in water in the PBS SOBP compared with the 327 
passive double scattering. 328 
 329 
C. Passive delivery SOBP field characterization 330 
Figure 8 shows the microdosimetric spectra obtained with the µ+ probe along the central axis of 331 
the DS SOBP (5×5×5cm3 dose cube) with R90 = 126 ± 1 mm. Measurements with the µ+ probe were 332 
taken at depths of 22, 50, 90, 100, 110, 122, 125, 126, 128, 130, 140 and 150mm in water. 333 
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a) b) 
Figure 8 Microdosimetric spectra obtained with the µ+ probe at different depths; a) 22-122 mm and b) 125-334 
150mm in a water phantom for passively delivered 1.82 Gy dose cube with dimensions of  5 x 5 x 5 cm3  335 
 The lineal energy of the field ranged from 0.4 to 10 keV/µm at the plateau region, with multiple high 336 
LET events up to 100 keV/µm observed due to inelastic reactions which are, as mentioned above, 337 
associated with carbon, silicon recoils and Si(n,α) reactions. A lineal energy variation from 0.4 to 20 338 
keV/µm was observed in the proximal part of the SOBP and from 0.5 to 50 keV/µm along the SOBP. 339 
Downstream of the SOBP, similar to PBS SOBP field, lineal energies up to 200 keV/µm were 340 
observed more clearly due to their statistically larger contribution in comparison to primary proton 341 
events in-field. 342 
Figure 9 shows the dose-mean lineal energy derived from the microdosimetric spectra at different 343 
depths in water for the passively delivered 5 × 5 × 5 cm3 SOBP beam. For this field, isocentre was set 344 
at 100 mm depth in water, a brass aperture with 5 × 5 cm2 projection was implemented in the 345 
treatment nozzle and 5.3 cm modulation was used to deliver the dose. 𝑦𝐷���� values in the DS beam were 346 
approximately 2 to 3 keV/µm at the shallow depths between 20 to 30 mm in water and then decreased 347 
to around 2 keV/µm between depths of 40 to 50 mm. This may be explained by secondary neutron 348 
production in the nozzle and scatter of lower energy protons from the aperture in the passive beam 349 
delivery system in contrast to the scanning beam.  The  𝑦𝐷���� values at greater depths increased slightly 350 
from 1.8 ± 0.15 keV/µm to 2.28 ± 0.25 keV/µm in the proximal part of the SOBP at depths of 50 mm 351 
to 70 mm, from 2.28 ± 0.25 keV/µm to 5.61 ± 0.11 keV/µm along the SOBP at depths from 70 mm to 352 
126 mm, and up to 7.24 ± 0.15 keV/µm at the distal part of the SOBP. Figure 10a shows the depth-353 
dose and RBE distributions derived from the microdosimetric spectra obtained with the µ+ probe for 354 
the DS SOBP field. Figure 10b shows a detailed view of these distributions in the distal part of the 355 
SOBP with 1mm increments. The derived RBE values for the planned absorbed dose of 2 Gy(RBE) at 356 
the SOBP were 0.98 ± 0.09 at the entrance, 0.96 ± 0.16 in the proximal part, which then increased 357 
from 1.01 ± 0.16 to 1.29 ± 0.17 along the SOBP and from 1.38 ± 0.18 to 1.43 ± 0.18 in the distal part 358 
of the SOBP.  359 
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 360 
Figure 9 Dose-mean lineal energy 𝑦𝐷��� obtained with the µ+ probe as a function of depth in water for the DS 361 
SOBP field with 5.3 cm modulation. 362 
 
 
 
 
a)                                                                                       b) 
Figure 10a) Depth-dose and RBE distributions for the DS SOBP field with 53 mm modulation. b) Detailed view 
of the depth-dose and RBE distributions from 100-135 mm depth in water. 
 
D. Geant4 modelling.  363 
D1. Pencil beam scanning simulation 364 
 Figure 11 shows the simulated individual proton spot depth-dose distribution compared to the 365 
measurements performed with the Zebra. The simulated results agree with the measured results within 366 
4.0% ± 0.6% at the entrance of the BP (up to 50 mm depth in water), 3.0% ± 0.5% in the plateau 367 
region, and within 1.0% ± 0.5 % around the BP. The measured dose was observed to be slightly 368 
higher than simulated. This may be explained by the difference of the water equivalent material used 369 
in the experimental measurement with the Zebra (polyethylene) and in the simulation (water) as the 370 
simulation was aimed to match the experimental setup.  371 
Figure 12 shows a comparison of the simulated and experimental response of the bridge 372 
microdosimeter in terms of the 𝑦𝐷���� distribution for the PBS spot. The maximum energy deposited in 373 
the simulated silicon SV was set to 2450 keV to match the maximum energy in MCA spectra 374 
measured with the µ+ probe in the experiment. Good agreement was observed between the simulated 375 
and experimentally derived 𝑦𝐷���� along the central axis of the field.   376 
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Figure 11 Simulated and experimental depth-dose 
distribution for the 131 MeV pencil beam in water. 
Figure 12 Comparison of simulated and experimental 𝑦𝐷��� 
values of the Bridge microdosimeter for a 131MeV 
pencil beam. 
D2. Average path length simulation of the bridge microdosimeter using a PBS spot. 377 
 378 
Figure 13 The mean path length of primary protons and secondary ions at various depths along 131 MeV 379 
protons in the water phantom for a bridge microdosimeter 380 
Figure 13 shows the simulated values of the mean path length for primary protons and secondary ions 381 
at various depths along the 131 MeV proton pencil beam using the bridge microdosimeter.  The mean 382 
path length of protons in the SV of the bridge microdosimeter was determined to be 9.647 ± 0.001 µm 383 
and 9.528 ± 0.004 µm at plateau of the BP (depth 22 and 110 mm, respectively), 9.488 ± 0.002 µm 384 
and 9.472 ± 0.005 at the proximal part of the BP (depth 122 and 125 mm, respectively). The 385 
secondary ions consists mostly of proton recoils generated by neutrons and have a wider angular 386 
spread therefore the mean path length of secondary ions are slightly larger than those of the primary 387 
protons and closer to the isotropic value of average chord length 12 µm.  Before the end of the BP, the 388 
primary protons dominate much more than secondary ions created therefore the mean path length 389 
values of primary protons were used to determine the lineal energy spectra at different depths. The 390 
variation of the average path length at different depths originates from the change in the protons 391 
tendency to scatter with depth and an increasing partial contribution of scattered protons induced by 392 
neutrons, especially downstream of the SOBP. 393 
E. Discussion.  394 
 The 𝑦𝐷���� values for both PBS and DS delivered beams obtained using the µ+ probe in a water 395 
phantom differs from the commonly used simulated LETd values found in literature, which is not 396 
unexpected. In the SOBP plateau region the 𝑦𝐷���� values obtained with the µ+ probe are approximately 2 397 
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keV/µm while the average LETd values are lower at about 1 keV/µm, depending on the method of 398 
LET scoring and voxel size. Due to time limitations of Monte Carlo generated LET distributions for 399 
RBE calculations, the voxel size is usually set to 1 - 2 mm in water [33, 34]. Cortes-Giraldo and 400 
Carabe have shown that by reducing the voxel size to 0.2 mm, the LETd for the primary proton beam 401 
increases by 1.8 times in the plateau SOBP region (from 1 keV/µm to about 2 keV/µm) [33]. This can 402 
be explained by the track structure of the protons which determine energy deposition by delta 403 
electrons within the voxel (e.g. SV) and the LETd is not changing proportionally to the linear size of 404 
the voxel. The same effect has been demonstrated using different delta electron range cut-off values in 405 
Monte Carlo simulations. By reducing the delta electron range cut-off from 0.05 mm to 0.01 mm, the 406 
LETd increased from approximately 1 to 2 keV/µm in the plateau region of a 200 MeV monoenergetic 407 
proton beam. This was due to low energy delta electrons contributing to the energy deposition in the 408 
voxel and thus increasing LET [31]. A combination of these factors explains the larger measured 𝑦𝐷���� 409 
values in the BP plateau region obtained with a SV size of 30 x 30 x 10 µm3, compared to the 410 
simulated LETd in the PBS and DS SOBP deliveries. On the other hand, 𝑦𝐷���� and LETd values are 411 
similar in the distal parts of the spot BP (up to 10keV/µm) and DS SOBP (up to 7.5 keV/µm) where 412 
the range of most delta electrons is shorter than the size of the pixels used in LETd simulations [33, 413 
34] and, in this case, the size of the voxels is not critical for LET simulations. However, the regional 414 
microdosimetry approach with SV sizes comparable to biological cells such as in µ+ probe will 415 
provide more accurate RBE predictions than its surrogate LETd since the LET increases sharply in 416 
this region of the BP. The high spatial resolution µ+ probe is a unique tool which is independent of 417 
scoring method but rather reflects the energy stochastically deposited by primary proton tracks and all 418 
secondary charged particles on a cellular level, event by event, as required by regional 419 
microdosimetry. It can thus be used for fast 𝑦𝐷���� QA and model based RBE prediction. 420 
This study shows that for HSG cells, the maximum RBE at the end of the distal part of the PBS 421 
and DS SOBP was approximately 1.55 and 1.4, respectively for 1.82 Gy dose delivered at the BP or 422 
in the middle of the SOBP. This shows that the commonly used RBE value for proton therapy of 1.1 423 
should be reconsidered for the last several millimetres of the SOBP. It has been shown that the 424 
biological dose at the distal edge of the SOBP is underestimated by about 15-20 % for acute exposure 425 
(see Figure 12 in [16]) or even higher 25-30% in the case of fractionated exposure (Figure 5 in 426 
[3])when using RBE value of 1.1. This work has demonstrated an increased 𝑦𝐷���� and corresponding 427 
RBE calculated towards the distal part of the SOBP in PBS and passive proton therapy beam obtained 428 
using the high resolution solid state µ+ probe. The results shown in this work agree with experimental 429 
data obtained with human fibroblast cells for acute dose exposure [3]. Results from this work also 430 
agree with RBE values of 1.5 and 1.35 obtained using Monte Carlo Damage Simulation (MCDS) code 431 
for the distal part of the BP for a mono-energetic and modulated 160 MeV proton beam respectively 432 
for the ending point corresponding to the induction of double strand breaks (DSB) in DNA [16]. 433 
Good agreement was observed between the Monte Carlo simulated response of the bridge 434 
microdosimeter and the experimentally measured response, providing confidence in understanding the 435 
underlying physical processes involved in the measurements.  436 
Customizing the average path length of the SV with depth does not significantly improve the 437 
accuracy in the 𝑦𝐷���� distribution in a field, however using different average chord sizes downstream of 438 
the SOBP, where neutron produced recoil protons are scattered more isotropically, is advantageous 439 
for more accurate dose equivalent derivations. The recommended average path length for the SOI 440 
bridge microdosimeter is 9.60 ± 0.15 µm for in-field and 10.0 ± 0.5 µm for out-of-field.    441 
The presented results have demonstrated that the newly developed and easy-to-use 442 
microdosimetric probe allows for measurements of the dose mean lineal energy 𝑦𝐷���� in proton 443 
therapeutic beam with high spatial resolution. Calculated RBE values for a proton beam depend on 444 
the radiobiological models utilizing the measured 𝑦𝐷���� and can vary different for different models, cell 445 
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lines and ending points. The presented RBE values along the BP in this paper correspond to HSG 446 
cells only and are calculated based on the MKM.  447 
   IV. Conclusion 448 
 The proton beam at the Massachusetts General Hospital, using both PBS and DS delivery modes, 449 
was characterized in detail using the high spatial resolution 3D bridge microdosimeter from the 450 
CMRP. The MKM based RBE distributions for HSG cells, derived from the microdosimetric 451 
measurements, have shown that for an individual PBS spot, the RBE increased gradually at the 452 
plateau and proximal part of the BP from approximately 0.96 to 1.03, then rose to 1.11 at the BP and 453 
increased substantially to 1.57 in the distal part of the BP. This study demonstrated that the RBE in 454 
the distal part of the BP and SOBP changes significantly, especially in the last 3 to 4 mm of the proton 455 
range, where the absorbed dose is still relatively high. The RBE value of 1.1 currently implemented in 456 
most proton therapy centres worldwide could essentially underestimate the biological dose at the end 457 
of the proton range. 458 
The dose equivalent 10 cm away from the edge of a PBS SOBP field proved to be significantly 459 
less than that of a SOBP field using DS [31]. This supports the justification of using a PBS system for 460 
reducing the risk of secondary cancer induction. The dose equivalent downstream of the SOBP using 461 
PBS was of the same order as that obtained using DS. No observable benefit was observed 462 
downstream of the treatment volume when comparing PBS to DS. 463 
The Geant4 simulated depth-dose for a 131MeV proton pencil beam agreed reasonably well with 464 
the experimental results obtained with the Zebra within around 4 ± 0.6% at the entrance and within 1 465 
± 0.5% at the BP. The mean path length of the microdosimeter SV was simulated at different depths 466 
in water for a proton pencil beam in order to obtain more accurate lineal energy determination.   467 
This study presented a new and fast characterisation tool in proton therapy for PBS and DS 468 
systems using a silicon microdosimeter containing 3D SVs. This microdosimetric probe has been 469 
tested to be applied for proton and ion beam characterisation with sub-millimetre spatial resolution; it 470 
showed great promise as an experimental device for microdosimetric spectra measurements and 471 
commissioning of RBE values used in the treatment planning system.  472 
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